Peptide Based Metabolic Disorders Therapeutics Market Anticipated to Show a Value US$ 8 Bn until 2022

Posted on 2018-06-05 by Mark Hub in Healthcare // 0 Comments

Fact.MR

Dublin 2, Ireland, 2018-Jun-05 — /EPR Network/ — Recently, a novel report developed using proven research methodologies at the headquarters of Fact. MR has identified various prominent factors and trends prompting market growth of peptide based metabolic disorders therapeutics market. The study is titled as “Peptide Based Metabolic Disorders Therapeutics Market Forecast, Trend Analysis & Competition Tracking: Global Review 2017 to 2022”, which deeply analyses the global market trends, with historical data from 2016 and 2017, and projections of compound annual growth rates (CAGRs) during the mentioned forecast of 2017-2022. For the benefit of the readers, the report concludes with a special focus on the detailed profiles of the major vendors in the global peptide based metabolic disorders therapeutics market.

Request for Sample Report- https://www.factmr.com/connectus/sample?flag=S&rep_id=187

Ongoing research and development activities have maintained their focus on treatments for human ailments. The peptide therapeutics is used to treat various ailments, one such being the metabolic disorders. The global peptide based metabolic disorders therapeutics market is positively impacted by factors such as efficacy, safety, innovations in drug discovery, easy synchronization, stability, etc. Moreover, in addition to these factors, certain economic aspects also fuel the growth of the global peptide based metabolic disorders therapeutics market. The increasing investment in the healthcare industry and in research, the technological advancements, rise in biotech and pharmaceutical companies dealing with peptides. The increase in the metabolic disorder rate has made it imperative to develop new treatments with peptides and this has spurred the adoption of peptide therapeutics in the treatment of metabolic disorders, thereby contributing to the growth of the global peptide based metabolic disorders therapeutics market.

The global peptide based metabolic disorders therapeutics market is anticipated to show a value more than US$ 8 Bn and expected to grow at a robust rate during the period of forecast.

3 Forecast Highlights on Global Peptide Based Metabolic Disorders Therapeutics Market

1. North America expected to grow at the highest CAGR to reflect a growth rate of 10.6% during the period of forecast as well as dominate the global market in terms of market share by revenue, as of 2017. It can be said that this trend would be followed, considering the technological developments, and the higher investments in the healthcare industry that this segment portrays, and retain its dominant position by the end of 2022, at least

2. Asia-Pacific excluding Japan (APEJ) region also anticipated to grow at a similar growth rate as of North America region, yet does not portray high market share by revenue. The market share by revenue of APEJ is less than one third than that of North America region and less than half of the market revenue share of the Europe region

3. Liraglutide segment by drug class is expected to grow at a robust rate during the period of forecast and dominates the market by drug class in terms of market share by revenue as of 2017. However, the growth rate of this segment is comparatively low than that of the other two segments by drug class

Browse Full Report with TOC- https://www.factmr.com/report/187/peptide-based-metabolic-disorders-therapeutics-market

APEJ Shows a Similar Growth Rate

The Asia-Pacific excluding Japan (APEJ) region had shown rapid growth in the past with respect to global peptide based metabolic disorders therapeutics market, and is poised to reflect a higher growth rate, as fast as North America. APEJ will register a CAGR of 10.5% during the forecast period. The main reasons for this kind of growth is the strict government regulations for the upcoming players, higher number of pharmaceutical companies, increased foreign direct investment and development of technologies. Moreover, the government encourages to increase the investment in the healthcare industry to discover and invent new methods & technologies to better the health of the patients and enhance treatment outcomes. Europe region, following APEJ region, also reflects itself as a positive platform for the growth of the global peptide based metabolic disorders therapeutics market.

Hospital Pharmacies Segment Shows Supremacy, Online Pharmacy Shows Growth

The hospital pharmacies segment by distribution channel reflect a higher market share by revenue and a higher growth rate throughout the period of forecast. However, the online pharmacies segment shows even higher growth rate as compared to hospital pharmacies segment, and is expected to register a CAGR of 11.8% during the period of forecast. But the market share of this segment is less; hospital pharmacies segment enjoys a market share more than three times than that of online pharmacies segment. The online pharmacies segment is expected to enjoy a gain in the BPS by the end of 2022. On the other hand, the retail pharmacies segment shows moderate growth rate, yet higher than that of the hospital pharmacies segment and a market share more than double than that of the online pharmacies segment as of 2017.

Competition Tracking

The report also profiles companies that are expected to remain active in the expansion of the global peptide based metabolic disorders therapeutics market through 2022, which include AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., PolyPeptide Group, Novo Nordisk A/S, Merck & Co., Inc., Ipsen S.A, Eli Lilly and Company, CordenPharma International, and Bachem Holding AG.

Request Methodology of the Report- https://www.factmr.com/connectus/sample?flag=RM&rep_id=187

About Fact.MR

Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized Healthcare market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that’s why we publish multi-industry global, regional, and country-specific research reports.

Matched content

Editor’s pick